Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ

$391.32

-$6.23 (1.57%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$390.00$402.33

Open $394.22

52 Week Range

$205.87$495.55

Previous Close $397.55

Market Cap52.21B

Volume1.17M

Avg Volume1.20M

P/E (TTM)1192.29

EPS (TTM)$0.33

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Alnylam Pharmaceuticals, Inc.

DEC112025

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Source: Business Wire•4 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of ...

DEC32025

Alnylam Pharmaceuticals Announces Changes to Board of Directors

Source: Business Wire•12 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independe...

NOV82025

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

Source: Business Wire•37 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ap...

OCT302025

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Source: Business Wire•46 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business high...

OCT162025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Source: Business Wire•60 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 202...

OCT12025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

Source: Business Wire•75 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a glob...

SEP282025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Source: Business Wire•78 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved fo...

SEP182025

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Source: PRNewsWire•88 days ago

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries be...